Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications

Price, 2004, Mesothelioma trends in the United States, Am J Epidemiol, 159, 107, 10.1093/aje/kwh025 Weill, 2004, Changing trends in US mesothelioma incidence, Occup Environ Med, 61, 438, 10.1136/oem.2003.010165 Greene, 2002, Pleural mesothelioma, 179 Khalil, 2003, Advances in the management of malignant mesothelioma, Curr Oncol Rep, 5, 334, 10.1007/s11912-003-0076-9 Sugarbaker, 1999, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 117, 54, 10.1016/S0022-5223(99)70469-1 Ahamad, 2003, Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest, Cancer J, 9, 476, 10.1097/00130404-200311000-00008 Nowak, 2002, New approaches for mesothelioma, Semin Oncol, 29, 82, 10.1053/sonc.2002.30234 Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136 Yoshino, 2004, Multimodal treatment for resectable epithelial type malignant pleural mesothelioma, World J Surg Oncol, 2, 11, 10.1186/1477-7819-2-11 Zellos, 2002, Multimodality treatment of diffuse malignant pleural mesothelioma, Semin Oncol, 29, 41, 10.1053/sonc.2002.30230 Catalano, 2004, Experimental therapy of malignant mesothelioma, Crit Rev Oncol Hematol, 50, 101, 10.1016/j.critrevonc.2003.10.001 Rusch, 1995, A proposed new international TNM staging system for malignant pleural mesothelioma, Chest, 108, 1122, 10.1378/chest.108.4.1122 Patz, 1992, Malignant pleural mesothelioma, AJR Am J Roentgenol, 159, 961, 10.2214/ajr.159.5.1414807 Heelan, 1999, Staging of malignant pleural mesothelioma, AJR Am J Roentgenol, 172, 1039, 10.2214/ajr.172.4.10587144 Nanni, 2004, Role of 18f-FDG PET for evaluating malignant pleural mesothelioma, Cancer Biother Radiopharm, 19, 149, 10.1089/108497804323071913 Gerbaudo, 2002, Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging, J Nucl Med, 43, 1144 Flores, 2003, Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 126, 11, 10.1016/S0022-5223(03)00207-1 Schneider, 2000, Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 120, 128, 10.1067/mtc.2000.106529 Benard, 1998, Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography, Chest, 114, 713, 10.1378/chest.114.3.713 Zubeldia, 2000, 11, Clin Positron Imaging, 3, 165, 10.1016/S1095-0397(00)00077-7 Mountain, 1997, Regional lymph node classification for lung cancer staging, Chest, 111, 1718, 10.1378/chest.111.6.1718 Rusch, 1996, The importance of surgical staging in the treatment of malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 111, 815, 10.1016/S0022-5223(96)70342-2